AKTing on XPO1 inhibition in AML

Nat Cancer. 2022 Jul;3(7):787-789. doi: 10.1038/s43018-022-00395-w.
No abstract available

Publication types

  • Comment

MeSH terms

  • Humans
  • Karyopherins*
  • Leukemia, Myeloid, Acute* / drug therapy
  • Receptors, Cytoplasmic and Nuclear

Substances

  • Karyopherins
  • Receptors, Cytoplasmic and Nuclear